201 related articles for article (PubMed ID: 27023907)
1. A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.
Kang JJ; Liu IY; Wang MB; Srivatsan ES
Hum Genet; 2016 Jul; 135(7):675-84. PubMed ID: 27023907
[TBL] [Abstract][Full Text] [Related]
2. The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test.
Boizot A; Talmat-Amar Y; Morrogh D; Kuntz NL; Halbert C; Chabrol B; Houlden H; Stojkovic T; Schulman BA; Rautenstrauss B; Bomont P
Acta Neuropathol Commun; 2014 Apr; 2():47. PubMed ID: 24758703
[TBL] [Abstract][Full Text] [Related]
3. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.
Bomont P; Cavalier L; Blondeau F; Ben Hamida C; Belal S; Tazir M; Demir E; Topaloglu H; Korinthenberg R; Tüysüz B; Landrieu P; Hentati F; Koenig M
Nat Genet; 2000 Nov; 26(3):370-4. PubMed ID: 11062483
[TBL] [Abstract][Full Text] [Related]
4. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.
Mahammad S; Murthy SN; Didonna A; Grin B; Israeli E; Perrot R; Bomont P; Julien JP; Kuczmarski E; Opal P; Goldman RD
J Clin Invest; 2013 May; 123(5):1964-75. PubMed ID: 23585478
[TBL] [Abstract][Full Text] [Related]
5. Two novel mutations in the GAN gene causing giant axonal neuropathy.
Normendez-Martínez MI; Monterde-Cruz L; Martínez R; Marquez-Harper M; Esquitin-Garduño N; Valdes-Flores M; Casas-Avila L; de Leon-Suarez VP; Romero-Díaz VJ; Hidalgo-Bravo A
World J Pediatr; 2018 Jun; 14(3):298-304. PubMed ID: 29876741
[TBL] [Abstract][Full Text] [Related]
6. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.
Johnson-Kerner BL; Ahmad FS; Diaz AG; Greene JP; Gray SJ; Samulski RJ; Chung WK; Van Coster R; Maertens P; Noggle SA; Henderson CE; Wichterle H
Hum Mol Genet; 2015 Mar; 24(5):1420-31. PubMed ID: 25398950
[TBL] [Abstract][Full Text] [Related]
7. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy.
Mussche S; Devreese B; Nagabhushan Kalburgi S; Bachaboina L; Fox JC; Shih HJ; Van Coster R; Samulski RJ; Gray SJ
Hum Gene Ther; 2013 Feb; 24(2):209-19. PubMed ID: 23316953
[TBL] [Abstract][Full Text] [Related]
8. A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization.
Nath B; Julien JP
J Neurosci; 2023 May; 43(22):4174-4189. PubMed ID: 37137704
[TBL] [Abstract][Full Text] [Related]
9. Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment.
Chen PH; Hu J; Wu J; Huynh DT; Smith TJ; Pan S; Bisnett BJ; Smith AB; Lu A; Condon BM; Chi JT; Boyce M
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31944090
[TBL] [Abstract][Full Text] [Related]
10. Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis.
Johnson-Kerner BL; Roth L; Greene JP; Wichterle H; Sproule DM
Muscle Nerve; 2014 Oct; 50(4):467-76. PubMed ID: 24947478
[TBL] [Abstract][Full Text] [Related]
11. Giant axonal neuropathy caused by a novel compound heterozygous mutation in the gigaxonin gene.
Xu M; Da YW; Liu L; Wang F; Jia JP
J Child Neurol; 2013 Oct; 28(10):1316-9. PubMed ID: 23248352
[TBL] [Abstract][Full Text] [Related]
12. Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy.
Israeli E; Dryanovski DI; Schumacker PT; Chandel NS; Singer JD; Julien JP; Goldman RD; Opal P
Hum Mol Genet; 2016 Jun; 25(11):2143-2157. PubMed ID: 27000625
[TBL] [Abstract][Full Text] [Related]
13. Giant axonal neuropathy.
Hentati F; Hentati E; Amouri R
Handb Clin Neurol; 2013; 115():933-8. PubMed ID: 23931822
[TBL] [Abstract][Full Text] [Related]
14. Gigaxonin is required for intermediate filament transport.
Renganathan B; Zewe JP; Cheng Y; Paumier JM; Kittisopikul M; Ridge KM; Opal P; Gelfand VI
FASEB J; 2023 May; 37(5):e22886. PubMed ID: 37043392
[TBL] [Abstract][Full Text] [Related]
15. Clinicogenetical features of a Japanese patient with giant axonal neuropathy.
Akagi M; Mohri I; Iwatani Y; Kagitani-Shimono K; Okinaga T; Sakai N; Ozono K; Taniike M
Brain Dev; 2012 Feb; 34(2):156-62. PubMed ID: 21356581
[TBL] [Abstract][Full Text] [Related]
16. Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts.
Lowery J; Jain N; Kuczmarski ER; Mahammad S; Goldman A; Gelfand VI; Opal P; Goldman RD
Mol Biol Cell; 2016 Feb; 27(4):608-16. PubMed ID: 26700320
[TBL] [Abstract][Full Text] [Related]
17. Explaining intermediate filament accumulation in giant axonal neuropathy.
Opal P; Goldman RD
Rare Dis; 2013; 1():e25378. PubMed ID: 25003002
[TBL] [Abstract][Full Text] [Related]
18. Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.
Johnson-Kerner BL; Garcia Diaz A; Ekins S; Wichterle H
PLoS One; 2015; 10(10):e0140157. PubMed ID: 26460568
[TBL] [Abstract][Full Text] [Related]
19. Clinical, pathological and molecular findings in two siblings with giant axonal neuropathy (GAN): report from India.
Nalini A; Gayathri N; Yasha TC; Ravishankar S; Urtizberea A; Huehne K; Rautenstrauss B
Eur J Med Genet; 2008; 51(5):426-35. PubMed ID: 18595793
[TBL] [Abstract][Full Text] [Related]
20. The CRL3
Park HM; Le L; Nguyen TT; Nam KH; Ordureau A; Lee JE; Nguyen TV
Proc Natl Acad Sci U S A; 2023 Nov; 120(45):e2306395120. PubMed ID: 37903270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
